Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis (MODIFY)

Almirall

Status and phase: Terminated; Phase 4

Conditions: Plaque Psoriasis

Treatments: Biological: Tildrakizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT04339595

2019-003218-15 (EudraCT Number)

M-14745-44

Details and patient eligibility

About

The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory biomarkers and its correlation disease relapse.

Enrollment: 47 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants provide signed written informed consent prior to perform any study-related activity
• Participants has completed the long-term extension of the reSURFACE 2 study

Exclusion criteria

• Participants unable to comply with the requirements of the study
• Participants who in the opinion of the investigator should not participate in the study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

47 participants in 1 patient group

Tildrakizumab

Experimental group

Treatment:

Biological: Tildrakizumab